*After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months during your first year of treatment. Dosing may vary.
*After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months during your first year of treatment. Dosing may vary.
*After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months during your first year of treatment. Dosing may vary.
WATCH THE VIDEO
Hero VO:
With wet AMD, sometimes I worry my world is getting smaller because of my sight. But now, I can open up my world with VABYSMO.
VABYSMO is the first FDA-approved treatment for people with wet AMD that improves vision and delivers a chance for up to 4 months between treatments. Which means doing more of what I love.
Announcer VO:
VABYSMO is the only treatment designed to block 2 causes of wet AMD. VABYSMO is an eye injection. Don’t take it if you have an infection or active swelling in or around your eye, or are allergic to it or any of its ingredients.
Treatments like VABYSMO can cause eye infection or retinal detachment. VABYSMO may cause a temporary increase in eye pressure after receiving the injection.
Although uncommon, there is a potential risk of heart attack or stroke associated with blood clots.
Hero VO:
Open up your world!
Announcer VO:
A chance for up to 4 months between treatments with VABYSMO. Ask your doctor.
†In clinical trials of 665 people on VABYSMO and 664 people on aflibercept, people gained an average of 5 letters on an eye chart at 1 month for both treatments. On average, people gained and maintained 6 letters over 1 year with VABYSMO, similar to aflibercept.
‡After 4 initial monthly eye injections, your doctor will choose a schedule of 1 to 4 months during your first year of treatment. Dosing may vary.
§The benefit of blocking Ang-2 has not been fully determined.
Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
With VABYSMO, I’m not having to run back and forth for my injections as much as I was. We have more time to do things now with the family.
Patient experiences may vary.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.